Number: CALGB 50303 Principal Investigator: Bartlett, Nancy
Title: Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
Phase: III Disease Site: Non-Hodgkin's Lymphoma
Participating Site(s):
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
Contact: 800-600-3606 or

The purpose of this study is to compare the effects, good and/or bad of two treatments (called R-CHOP with Dose-Adjusted EPOCH-R [DA-EPOCH-R, for short]) on patients and their lymphoma to find out which is better. Currently, R-CHOP is considered standard of care (that is, a treatment that is widely used by most physicians) for lymphoma, while DA-EPOCH-R is a newer treatment developed over the last 14 years.

Another important goal of the study is to analyze tumors using new scientific laboratory studies to better understand types of lymphoma. This will allow doctors to perform important scientific research studies that may help determine if one of these treatments is more effective in certain types of lymphomas.

About 478 people will take part in this study with approximately 30 people at Washington University.
More Information: Link
Internal Protocol Documents (requires Siteman administrative database password)